<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956709</url>
  </required_header>
  <id_info>
    <org_study_id>BRD/08/05-D</org_study_id>
    <nct_id>NCT00956709</nct_id>
  </id_info>
  <brief_title>Regional Anesthesia for Major Surgery of the Foot. Levobupivacaïne Ropivacaine 0.5% Versus 0.5% in the Sciatic Block Through médiofémorale</brief_title>
  <acronym>SCIALERO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ropivacaine 0.5% and 0.5% in levobupivacaïne are used in regional anesthesia for major
      surgery of the foot. The literature does not highlight a significant difference in terms of
      onset of action between these two molecules to block the sciatic nerve [4]. Our hypothesis is
      that this lack of difference is due to the use of a neurostimulator for locating the
      injection site (indiscriminate nature of the anatomical approach to the sciatic nerve).
      Indeed, the sensitivity of neurostimulation is low compared with ultrasound [58] and
      ultrasound, for accurate visualization of the deposit of the local anesthetic around the
      nerve to improve the quality of the block and reduce the onset of action of local anesthetic
      [46, 47].

      The investigators propose to make a comparative trial between levobupivacaïne 0.5%
      ropivacaine and 0.5% under the control of the ultrasound as part of a sciatic nerve block.
      The use of ultrasound will reduce the variability of results because the changes would be
      linked exclusively to the local anesthetic. The investigators test the hypothesis that
      levobupivacaïne gives better results in terms of onset of action than ropivacaine.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the Onset of Action of Ropivacaine 0.5% and levobupivacaïne 0.5 % for Sciatic Nerve Block Guided in Major Surgery of the Foot</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Relative Position of the Tibial and Contigent Fibulaire Common in the Sciatic Nerve.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Motor Sciatic Block (h)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Sensory Sciatic Block (h)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Nerve Block</condition>
  <arm_group>
    <arm_group_label>Levobupivacaïne 0,5 %</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaïne 0,5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levobupivacaïne 0,5 %</intervention_name>
    <description>20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %</description>
    <arm_group_label>Levobupivacaïne 0,5 %</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaïne 0,5 %</intervention_name>
    <description>20mL de ropivacaïne 0,5 %</description>
    <arm_group_label>Ropivacaïne 0,5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unilateral major surgery of the foot: hallux valgus (not ambulatory),
             claw toes, fusion-Astragalo calcaneum, complex syntheses of tarsus-aged over 18 years
             .

          -  Male and female

          -  ASA 1 or 2

          -  Insured Social

          -  Informed Consent

        Exclusion Criteria:

          -  Diabetes

          -  Intoxication-alcoholic chronic

          -  Allergy to local anesthetics

          -  Hemostasis disorders

          -  Hepatic failure

          -  Chronic pain syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <results_first_submitted>July 7, 2014</results_first_submitted>
  <results_first_submitted_qc>July 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2014</results_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Levobupivacaïne 0,5 %</title>
          <description>levobupivacaïne 0,5 %: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %</description>
        </group>
        <group group_id="P2">
          <title>Ropivacaïne 0,5%</title>
          <description>ropivacaïne 0,5 %: 20mL de ropivacaïne 0,5 %</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levobupivacaïne 0,5 %</title>
          <description>levobupivacaïne 0,5 %: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %</description>
        </group>
        <group group_id="B2">
          <title>Ropivacaïne 0,5%</title>
          <description>ropivacaïne 0,5 %: 20mL de ropivacaïne 0,5 %</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="36" upper_limit="83"/>
                    <measurement group_id="B2" value="62" lower_limit="35" upper_limit="75"/>
                    <measurement group_id="B3" value="62" lower_limit="35" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Compare the Onset of Action of Ropivacaine 0.5% and levobupivacaïne 0.5 % for Sciatic Nerve Block Guided in Major Surgery of the Foot</title>
        <time_frame>72 hours</time_frame>
        <population>Two patients in each group had incomplete block before surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>Levobupivacaïne 0,5 %</title>
            <description>levobupivacaïne 0,5 %: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaïne 0,5%</title>
            <description>ropivacaïne 0,5 %: 20mL de ropivacaïne 0,5 %</description>
          </group>
        </group_list>
        <measure>
          <title>Compare the Onset of Action of Ropivacaine 0.5% and levobupivacaïne 0.5 % for Sciatic Nerve Block Guided in Major Surgery of the Foot</title>
          <population>Two patients in each group had incomplete block before surgery.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="15" upper_limit="60"/>
                    <measurement group_id="O2" value="35" lower_limit="10" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>Two patients in each group had incomplete block before sugery.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Relative Position of the Tibial and Contigent Fibulaire Common in the Sciatic Nerve.</title>
        <time_frame>72 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Motor Sciatic Block (h)</title>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levobupivacaïne 0,5 %</title>
            <description>levobupivacaïne 0,5 %: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaïne 0,5%</title>
            <description>ropivacaïne 0,5 %: 20mL de ropivacaïne 0,5 %</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Motor Sciatic Block (h)</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.54" lower_limit="5.25" upper_limit="37.50"/>
                    <measurement group_id="O2" value="15.17" lower_limit="4.42" upper_limit="20.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3354</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Sensory Sciatic Block (h)</title>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levobupivacaïne 0,5 %</title>
            <description>levobupivacaïne 0,5 %: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaïne 0,5%</title>
            <description>ropivacaïne 0,5 %: 20mL de ropivacaïne 0,5 %</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Sensory Sciatic Block (h)</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.25" lower_limit="6.25" upper_limit="53.50"/>
                    <measurement group_id="O2" value="15.00" lower_limit="8.52" upper_limit="23.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0445</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Levobupivacaïne 0,5 %</title>
          <description>levobupivacaïne 0,5 %: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %</description>
        </group>
        <group group_id="E2">
          <title>Ropivacaïne 0,5%</title>
          <description>ropivacaïne 0,5 %: 20mL de ropivacaïne 0,5 %</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Pham Dang</name_or_title>
      <organization>CHU de Nantes</organization>
      <phone>33 2 53 48 24 15</phone>
      <email>charles.phamdang@chu-nantes.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

